MaurerJR, RyuJ, BeckGet al.Lung transplantation in the management of patients with lymphangioleiomyomatosis: Baseline data from the NHLBI LAM registry. J Heart Lung Transplant, 2007; 26:1293–1299.
2.
RyuJH, MossJ, BeckGJet al.The NHLBI Lymphangioleiomyomatosis Registry: Characteristics of 230 patients at enrollment. Am J Respir Crit Care Med, 2006; 173:105–111.
3.
KawanamiO, FerransVJ, CrystalRG. Subplasmalemmal linear densities in cells of the mononuclear phagocyte system in lung. Am J Pathol, 1980; 100:131–149.
4.
BassetF, FerransVJ, SolerP, TakemuraT, FukudaY, CrystalRG. Intraluminal fibrosis in interstitial lung disorders. Am J Pathol, 1986; 122:443–461.
5.
Taveira–DaSilvaAM, StylianouMP, HedinCJ, HathawayA, MossJ. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest, 2004; 126:1867–1874.
6.
AvilaNA, DwyerAJ, RabelA, MossJ. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: Comparison of CT features. Radiology, 2007; 242:277–285.
7.
NellistM, JanssenB, BrookcarterPTet al.Identification and characterization of the tuberous sclerosis gene on chromosome-16. cell, 1993; 75:1305–1315.
8.
vanSlegtenhorstM, deHoogtR, HermansCet al.Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science, 1997; 277:805–808.
9.
AvilaNA, DwyerAJ, Murphy–JohnsonDV, BrooksP, MossJ. Sonography of lymphangioleiomyoma in lymphangioleiomyomatosis: Demonstration of diurnal variation in lesion size. Am J Roentgenol, 2005; 184:459–464.
10.
Pacheco–RodriguezG, SteagallWK, CrooksDMet al.TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res, 2007; 67:10573–10581.
11.
CrooksDM, Pacheco–RodriguezG, DeCastroRMet al.Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA, 2004; 101:17462–17467.
12.
Pacheco–RodriguezG, KristofAS, StevensLA, ZhangY, CrooksD, MossJ. Genetics and gene expression in lymphangioleiomyomatosis. Chest, 2002; 121:56s–60s.
13.
Taveira–DaSilvaAM, StylianouMP, HedinCJet al.Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Resp Crit Care Med, 2003; 168:1427–1431.
14.
ChuSC, HoribaK, UsukiJet al.Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest, 1999; 115:1041–52.
15.
CarsilloT, AstrinidisA, HenskeEP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA, 2000; 97:6085–6090.
16.
SmolarekTA, WessnerLL, McCormackFX, MyletJC, MenonAG, HenskeEP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: Chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Human Genet, 1998; 62:810–815.
17.
KarbowniczekM, AstrinidisA, BalsaraBRet al.Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med, 2003; 167:976–982.
18.
KarbowniczekM, AstrinidisA, BalsaraBRet al.Recurrent lymphangiomyomatosis after transplantation: Genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med, 2003; 167:976–982.
19.
GoncharovaEA, GoncharovDA, EszterhasAet al.Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)J Biol Chem, 2002; 277:30958–30967.
20.
BisslerJJ, McCormackFX, YoungLRet al.Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med, 2008; 358:140–151.
21.
DaviesDM, JohnsonSR, TattersfieldAEet al.Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med, 2008; 358:200–203.
22.
PaulE, ThieleE. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. N Engl J Med, 2008; 358:190–192.
